Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025
Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO
Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC
Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies
Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC
Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients
Neal Shore, MD, FACS - Redefining Expectations in mHSPC: Options and Opportunities Across the Spectrum of Disease
Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?
Lorenza Rimassa, MD - Shifting the Paradigm in Biliary Tract Cancers: Contemporary Data and Decision-Making
Solange Peters, MD, PhD - Partnering With Patients: Shared Decision-Making in Locally Advanced, Unresectable EGFR-Mutated Non-Small Cell Lung Cancer
Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients
Adam Brufsky, MD, PhD / Rebecca Dent, MD, FRCP (Canada) - Same Class, Different Agents: Practical Considerations for Managing Toxicities of Interest in Patients on TROP2-Directed Therapies in Breast Cancer
Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer
Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy
Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer
Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed
Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?
Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma
Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions